☆ 4.6 Article

Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection

VIRUSES-BASEL (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Humoral response to SARS-CoV-2 vaccines in people living with HIV

Sebastian Noe et al.

Summary: This study found a strong antibody response in people living with HIV after receiving standard vaccination against SARS-CoV-2. Vaccination including an mRNA vaccine, being female, and having a higher CD4 cell count were significantly associated with higher antibody concentrations in people living with HIV.

INFECTION (2022)

添加到收藏夹

Article Immunology

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV

Zhengchao Lv et al.

Summary: HIV-positive individuals display weaker responses to inactivated SARS-CoV-2 vaccines, characterized by lower levels of neutralizing antibodies, possibly due to the low number of CD4 and B cells. This suggests that HIV-infected individuals may require additional doses or dose adjustment.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Immunology

Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults

Mark A. Brockman et al.

Summary: Humoral responses to COVID-19 mRNA vaccines are significantly weaker in older adults, and decline over time. Age is a significant predictor of antibody concentration and virus neutralizing activity, even after adjusting for participant demographics.

JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Virology

Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy

Eugenio Milano et al.

Summary: This study evaluated the immunogenicity and safety of the BNT162b2 vaccine in people living with HIV infection. The results showed that the vaccine regimen was immunogenic and well-tolerated in this population, with the majority of patients developing positive titer antibodies. No severe adverse events were reported.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia

Vladimir Petrovic et al.

Summary: This study compares the immunogenicity of different COVID-19 vaccines and finds that BNT162b2 and Gam-COVID-Vac vaccines have higher antibody levels compared to BBIBP-CorV vaccine. However, the immune response after BBIBP-CorV vaccine is similar to that seen in COVID-19 convalescents.

PLOS ONE (2022)

添加到收藏夹

Article Virology

Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China

Xiaojie Huang et al.

Summary: This study compared the immunogenicity of inactivated SARS-CoV-2 vaccines between people living with HIV (PLWH) and HIV-negative individuals. The results showed that PLWH had lower neutralizing activity, total antibody, S-IgG, and T-cell-specific immune response levels compared to HIV-negative individuals. Specific vaccination guidelines should be developed for PLWH.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Rheumatology

Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort

David Simon et al.

Summary: This study investigates the impact of bDMARD treatment on the immune response against SARS-CoV-2 in IMID patients. The results show that IMID patients treated with bDMARDs have lower prevalence of SARS-CoV-2 antibodies, lower seroconversion rate after infection, and reduced longevity of their immune response.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Lorenzo Azzi et al.

Summary: BNT162b2 COVID-19 vaccine induces strong systemic immune response but poorly activates mucosal immunity.

EBIOMEDICINE (2022)

添加到收藏夹

Article Immunology

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Ariel Israel et al.

Summary: This study demonstrates that individuals who received the Pfizer-BioNTech mRNA vaccine have higher initial levels of antibodies compared to patients who had been infected with the SARS-CoV-2 virus, but experience a much faster exponential decrease in antibody levels.

VACCINES (2022)

添加到收藏夹

Article Immunology

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Bezawit A. Woldemeskel et al.

Summary: Past studies have shown that some vaccines do not elicit optimal responses in individuals living with HIV. However, this study demonstrates that the BNT162b2 vaccine induces robust immune responses in these patients comparable to those in healthy donors.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Infectious Diseases

Antibody titers and protection against a SARS-CoV-2 infection

Chloe Dimeglio et al.

JOURNAL OF INFECTION (2022)

添加到收藏夹

Article Rheumatology

Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion

David Simon et al.

Summary: The study found that B cell depletion completely blocks humoral response to SARS-CoV-2 vaccination, but not T cell response. Limited humoral immune responses were observed in patients with B cell depletion after SARS-CoV-2 infection.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Immunology

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

Zabrina L. Brumme et al.

Summary: This study suggests that people living with HIV who have well-controlled viral loads and CD4+ T-cell counts in a healthy range generally have strong humoral responses to dual COVID-19 vaccination. Factors such as age, comorbidities, vaccine brand, response durability, and the emergence of new SARS-CoV-2 variants will impact when individuals with HIV will benefit from additional vaccine doses.

NPJ VACCINES (2022)

添加到收藏夹

Article Health Care Sciences & Services

Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study

Andrea Lombardi et al.

Summary: This study assessed the immunogenicity of the mRNA-1273 vaccine in people living with HIV (PLWHIV). The results showed that in PLWHIV with well-controlled ART, viral suppression, and CD4+ T cell count, inoculation with the mRNA-1273 vaccine produced detectable antibody response, similar to individuals without HIV infection.

LANCET REGIONAL HEALTH-EUROPE (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals

Katie Healy et al.

Summary: This study found that the mRNA BNT162b2 vaccine can induce immune responses in the saliva of immunocompromised individuals to SARS-CoV-2 spike antigens. Salivary responses were correlated with specific IgG titers and neutralizing capacity in serum, and had a high predictive power for identifying vulnerable groups for revaccination.

MED (2022)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study

Yanmeng Feng et al.

Summary: In this study, it was found that the inactivated COVID-19 vaccine was safe and immunogenic in HIV-1 infected individuals who are stable on cART. Participants did not experience significant adverse reactions after vaccination. Interestingly, HIV-infected individuals with low baseline CD4(+)/CD8(+) T cell ratios exhibited lower antibody responses post-vaccination compared to those with higher ratios.

ECLINICALMEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Allergy

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Carlo Cervia et al.

Summary: The study found that severe COVID-19 patients experienced a significant increase in SARS-CoV-2 antibody titers after symptom onset, especially with high IgA titers, while mild cases may exhibit transient production of SARS-CoV-2-specific antibodies. Interestingly, some healthcare workers with negative serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Chemistry, Analytical

Developing an Optical Interferometric Detection Method based biosensor for detecting specific SARS-CoV-2 immunoglobulins in Serum and Saliva, and their corresponding ELISA correlation

A. M. M. Murillo et al.

Summary: The paper presents a rapid, accurate, and cost-effective method for detecting antibodies against SARS-CoV-2, which can be used periodically for early detection, surveillance, immunity detection, and control of COVID-19 spread. The results obtained using this method were compared with those obtained using the traditional ELISA method.

SENSORS AND ACTUATORS B-CHEMICAL (2021)

添加到收藏夹

Article Virology

SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays

Gregory J. Walker et al.

Summary: Serological testing for SARS-CoV-2-specific antibodies plays a crucial role in understanding COVID-19 prevalence, incidence, and immune response. The study found a strong correlation between neutralising antibodies and certain commercially available EIAs, indicating their potential use in assessing protection post-infection or vaccination, and in screening convalescent plasma donors. The type of antibody and target antigen used in the assays were identified as crucial determinants of assay performance.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley et al.

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV

Aljawharah Alrubayyi et al.

Summary: The majority of people living with HIV on ART have detectable adaptive immune responses to SARS-CoV-2, with comparable humoral and T cell responses to HIV-negative subjects. T cell responses against Spike, Membrane and Nucleoprotein are prominent in both groups, with CD4 T cells outnumbering CD8 T cells. The magnitude of SARS-CoV-2-specific T cell responses is related to the size of the naive CD4 T cell pool and the CD4:CD8 ratio in people living with HIV, potentially impacting vaccine effectiveness and individual management.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Letter Virology

Assessment of salivary antibody response to BNT162b2 mRNA COVID-19 vaccination

Ivana Lapic et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study

Matthew Spinelli et al.

Summary: This study compared the SARS-CoV-2 infection rate, disease severity, and immune response between people living with HIV and those without HIV. The findings showed that although fewer infections were detected among people with HIV, they had more severe cases of COVID-19. Lower IgG concentrations and neutralising antibody titres in HIV-positive individuals suggest a diminished immune response to the infection.

LANCET HIV (2021)

添加到收藏夹

Article Immunology

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Jake A. Ruddy et al.

Summary: This study found uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres in 14 persons with HIV after two doses of mRNA vaccination, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

AIDS (2021)

添加到收藏夹

Article Infectious Diseases

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

Itzchak Levy et al.

Summary: The Pfizer-BioNTech BNT162b2 mRNA vaccine demonstrates immunogenicity and safety in people living with human immunodeficiency virus type 1 (PLWH) who are receiving antiretroviral therapy with unsuppressed CD4 count and suppressed viral load. Adverse events are mainly mild, such as pain at the injection site, fatigue, and headache. Immune response to the vaccine is strong, with high levels of anti-RBD-IgG and neutralizing antibodies observed in both PLWH and immunocompetent health-care workers.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

H. M. El Sahly et al.

Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Human IgG and IgA responses to COVID-19 mRNA vaccines

Adam Wisnewski et al.

Summary: Study on 4 subjects showed that COVID-19 mRNA vaccines effectively induce spike antigen-specific IgG and IgA, but there are marked differences in their persistence in serum.

PLOS ONE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Kizzmekia S. Corbett et al.

Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Matthias Becker et al.

Summary: This study characterizes the antibody response from vaccinated, infected, and uninfected individuals against emerging variants of concern of SARS-CoV-2, indicating reduced neutralization of a South African isolate. High IgG titers in the saliva of vaccinees suggest reduced transmission potential.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

John Frater et al.

Summary: The study demonstrates that the ChAdOx1 nCoV-19 vaccine is safe and immunogenic in people with HIV, with no serious adverse events reported. Local and systemic reactions were similar to those in HIV-negative participants, and antibody and cellular immune responses in HIV-infected individuals showed similar levels to those in uninfected individuals.

LANCET HIV (2021)

添加到收藏夹

Article Immunology

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Shabir A. Madhi et al.

Summary: This study aimed to assess the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV and HIV-negative individuals. The vaccine showed favorable safety and immunogenicity in people with HIV, including heightened immunogenicity in SARS-CoV-2 baseline-seropositive participants.

LANCET HIV (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Galia Rahav et al.

Summary: The antibody response to the Pfizer-BioNTech vaccine varied significantly among different immunocompromised patients, suggesting the need for individual recommendations based on specific immunosuppression states.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Raul Pellini et al.

Summary: The study found that 99.5% of healthcare workers developed a humoral immune response after vaccination, with female and young participants showing an increased capacity for humoral immune responses. Body mass index and hypertension seem to have no association with the differences in immune response to the vaccine.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Immunology

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Deborah Cromer et al.

Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Virology

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Kathleen G. Beavis et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

David Simon et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

ELISA detection of SARS-CoV-2 antibodies in saliva

Melanie A. MacMullan et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Immunology

Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease

Antigoni Morou et al.

NATURE IMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study

Kellie L. Hawkins et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Immune reconstitution and vaccination outcome in HIV-1 infected children Present knowledge and future directions

Alberto Cagigi et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)

添加到收藏夹

Article Immunology

Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count

Michael L. Landrum et al.

VACCINE (2009)

添加到收藏夹

Article Immunology

Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy

Alessandra Vigano et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)

添加到收藏夹

Review Immunology

HIV infection and the gastrointestinal immune system

J. M. Brenchley et al.

MUCOSAL IMMUNOLOGY (2008)

添加到收藏夹

Article Immunology

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy

PW Hunt et al.

JOURNAL OF INFECTIOUS DISEASES (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.